The role of patient advocacy organizations in shaping genomic science
- PMID: 23875802
- DOI: 10.1146/annurev-genom-091212-153525
The role of patient advocacy organizations in shaping genomic science
Abstract
Patient advocacy organizations (PAOs) are nonprofit groups that represent patients and families affected by a significant medical condition or disease. We review some of the different approaches that humanities and social researchers use to study PAOs. Drawing on this recent scholarship, we describe some contemporary patient groups and explore how PAOs can collaborate with biomedical researchers to advance genomic science. We highlight research that aims to describe how PAOs are contributing to multiple aspects of biomedical research, including study design, definition of research goals, data collection and analysis, dissemination of results, and research funding. We also describe several challenges that genomic researchers may encounter in collaborations with PAOs. Throughout our review, we focus on the manner in which new PAO roles challenge traditional boundaries between researchers and subjects, thereby redefining the relationship of patients to science. We consider how this shift may affect our view of scientific collaborations and impact genomic researchers in the future.
Similar articles
-
Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.JAMA Intern Med. 2017 Mar 1;177(3):344-350. doi: 10.1001/jamainternmed.2016.8443. JAMA Intern Med. 2017. PMID: 28114624
-
Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.J Law Med Ethics. 2013 Fall;41(3):680-7. doi: 10.1111/jlme.12078. J Law Med Ethics. 2013. PMID: 24088159 Free PMC article.
-
Generating sociability to drive science: patient advocacy organizations and genetics research.Soc Stud Sci. 2011 Feb;41(1):31-57. doi: 10.1177/0306312710385852. Soc Stud Sci. 2011. PMID: 21553639
-
Forging stronger partnerships between academic health centers and patient-driven organizations.Acad Med. 2013 Sep;88(9):1220-4. doi: 10.1097/ACM.0b013e31829ed2a7. Acad Med. 2013. PMID: 23887007 Review.
-
Participatory Genomic Research: Ethical Issues from the Bottom Up to the Top Down.Annu Rev Genomics Hum Genet. 2017 Aug 31;18:357-367. doi: 10.1146/annurev-genom-091416-035230. Epub 2017 Apr 19. Annu Rev Genomics Hum Genet. 2017. PMID: 28426284 Review.
Cited by
-
Realizing Our Potential in Biobanking: Disease Advocacy Organizations Enliven Translational Research.Biopreserv Biobank. 2016 Aug;14(4):314-8. doi: 10.1089/bio.2015.0053. Epub 2016 Apr 8. Biopreserv Biobank. 2016. PMID: 27058463 Free PMC article.
-
Pharmaceutical policy and innovation for rare diseases: A narrative review.F1000Res. 2023 Nov 13;12:211. doi: 10.12688/f1000research.130809.2. eCollection 2023. F1000Res. 2023. PMID: 38778810 Free PMC article. Review.
-
The involvement of patient organisations in rare disease research: a mixed methods study in Australia.Orphanet J Rare Dis. 2016 Jan 12;11:2. doi: 10.1186/s13023-016-0382-6. Orphanet J Rare Dis. 2016. PMID: 26754025 Free PMC article.
-
Advocacy in Action: Leveraging the Power of Patient Voices to Impact Ovarian Cancer Outcomes in Canada.Curr Oncol. 2022 Feb 18;29(2):1252-1261. doi: 10.3390/curroncol29020106. Curr Oncol. 2022. PMID: 35200605 Free PMC article.
-
The involvement of rare disease patient organisations in therapeutic innovation across rare paediatric neurological conditions: a narrative review.Orphanet J Rare Dis. 2022 Apr 18;17(1):167. doi: 10.1186/s13023-022-02317-6. Orphanet J Rare Dis. 2022. PMID: 35436886 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources